O le Kintor Pharmaceutical Limited i aso nei na faasilasila mai ai ua maeʻa e le kamupani le lesitalaina o tagata mamaʻi e 160 mo lona vaega II faʻataʻitaʻiga o le KX-826 ("pyrilutamide") i Saina mo le togafitia o le fafine androgenetic alopecia (AGA) i le aso 4 Mati 2022, lea e na o le XNUMX Mati XNUMX. e tusa ma le fa masina talu ona fa'alauiloa.

O le faitau aofaʻi o i latou o loʻo mafatia i le paʻu o lauulu o loʻo i ai se numera tele ma e foliga mai e laiti, ma o le paʻu o lauulu ua faasolosolo malie lava ona avea ma taulaiga o le sosaiete atoa. I le faaiuga o le 2020, o le numera o lauulu gau i Saina ua sili atu i le 252 miliona. AGA, ua lauiloa o le ituaiga sili ona taatele o lauulu gau, o se tulaga e mafai ona aafia uma ai alii ma tamaitai. I Saina, o le taatele o le AGA e tusa ma le 21.3% i tane ma le 6.0% i fafine *.

Fai mai Dr. Youzhi Tong, na faavaeina, Taitaifono, ma le Pule Sili o Kintor Pharma, "Matou te fiafia e vaai i le maeʻa o le lesitalaina o mataupu uma i le vaega II o suʻesuʻega falemaʻi o le KX-826, ma ou te fia avatu le faʻafetai faapitoa i tagata suʻesuʻe uma, mataupu ma laʻu 'au na auai i lenei suʻega faʻapitoa. I Saina, e tasi i le 20 tamaitai matutua e mafatia i le gau o lauulu, ma o le fua faatatau i alii matutua e 5:1. O le gau o lauulu e iai se aafiaga taua i le soifua maloloina o le mafaufau ma le lelei o le olaga o tagata mamaʻi. Matou te tulimatai atu i le mauaina o faʻamatalaga muamua mai lenei suʻesuʻega i le Q4 i lenei tausaga, faʻalautele atili le gafatia o le KX-826 i fafine AGA maʻi, ma faʻavavevave le KX-826's vaega III faʻataʻitaʻiga faʻataʻitaʻiga mo tamaʻitaʻi AGA i Saina, ina ia ausia le mana'omia togafitiga o tagata o lo'o mafatia i le pa'u o lauulu i se taimi vave lava."

O le faʻataʻitaʻiga o le vaega II o se suʻesuʻega faʻapitoa, lua-tauaso, placebo-pulea, suʻesuʻega faʻaitulagi e iloilo ai le aoga ma le saogalemu o le KX-826 mo le togafitiga o le AGA i fafine matutua (N = 160).

OA MEA E AVEA MAI LENEI TUSI:

Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma commented, “We are delighted to see the completion of the enrollment of all subjects in the phase II clinical trial of KX-826, and I would like to give special thanks to all the investigators, subjects and my team who participated in this clinical trial.
We look forward to receiving preliminary data from this study in Q4 this year, further broadening the clinical potential of KX-826 in female AGA patients, and accelerating KX-826’s phase III clinical trial for male AGA patients in China, so as to meet the treatment needs of people suffering from hair loss as soon as possible.
The population of those who suffer from hair loss has a large number and tends to be younger, and hair loss is gradually becoming the focus of the whole society.